To the best of our knowledge, this is the first study to demonstrate a robust correlation between elevated Ki67 expression, low PR levels, and HER2 overexpression, which are indicative of aggressive DCIS phenotypes. Here, ERBB2 is linked to ductal breast carcinoma in situ.